腹腔热灌注联合静脉化疗治疗晚期卵巢癌的疗效观察

目的:探讨晚期卵巢癌行腹腔热灌注联合静脉化疗的临床疗效及不良反应。方法:2008年12月-2012年12月收治的100例晚期卵巢癌并大、中量腹腔积液患者采用信封法随机分为治疗组和对照组。治疗组60例，行腹腔热灌注联合静脉化疗；对照组40例，行单纯的静脉化疗。治疗组采用顺铂腹腔热灌注联合紫杉醇静脉化疗，对照组采用紫杉醇联合顺铂静脉化疗，观察两组的腹水控制率及不良反应。结果:治疗组的腹水控制率为78.3%，对照组为42.5%，差异具有统计学意义（P＜0.01）。两组的不良反应比较无统计学差异（P＞0.05）。结论:腹腔热灌注联合静脉化疗可有效的控制卵巢癌患者恶性腹腔积液，不良反应能够耐受。

The clinical study of intraperitoneal hyperthermal chemotherapy combined with intrave-nous chemotherapy in the treatment of advanced ovarian cancer

Intraperitoneal hyperthermic chemotherapy（IHCT）has been used in the treatment of ovari-an cancer,to determine the efficacy of IHCT combined with intravenous chemotherapy in the treatment of advanced o-varian cancer. Methods：From 2008 to 2012,100 patients with advanced ovarian cancer were enrolled in a prospective nonrandomized study to undergo IHCT combined with intravenous chemotherapy. There were 60 cases in the treatment group,receiving intraperitoneal hyperthermal chemotherapy with DDP and intravenous chemotherapy with PTX. There were 40 cases in the control group,receiving intravenous chemotherapy with PTX and DDP. The ascites control rate and the main side effects were observed in the two groups. Results：The ascites control rate was 78. 3% in the treat-ment group and 42. 5% in the control group,with a significant difference between the two groups（P ﹤ 0. 01）. The rates of the main side effects in the two groups were not significantly different（P ﹥ 0. 05）. Conclusion：The effect of IHCT combined with intravenous chemotherapy on advanced ovarian carcinoma is better than that of intravenous chemotherapy alone and is a well - tolerated,feasible,and promising method of treatment in advanced ovarian cancer.